ReviewMolecular biology research communications2016
Epigenetics in diagnosis of colorectal cancer.
Review in Molecular biology research communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis indicating that high ALCAM expression predicts poor prognosis in colorectal cancer.Oncotarget · 2017Pooled it
- The methylation-expression correlation of autophagy-related genes in colorectal cancer patients from southern Iran.Molecular biology research communications · 2025Article
- Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis.Journal of medicine and life · 2024Review
- A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions.Cancer medicine · 2023Article
- Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.Journal of clinical laboratory analysis · 2021Article
- DNA Methylation Profiling of MYC, SMAD2/3 and DNMT3A in Colorectal Cancer.Oman medical journal · 2021Review
- Article
- Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.Bioscience reports · 2021Article
- Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction.Clinical epigenetics · 2020Article
- O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.Nature reviews. Clinical oncology · 2017Review
- Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients.Oncotarget · 2017Article
- Global perspective on colonoscopy use for colorectal cancer screening: A multi-country survey of practicing colonoscopists.Contemporary clinical trials communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a third most common epithelial carcinoma. CRC is known to develop from the early precancerous lesion to full blown malignancy via definite phases due to cumulative mutations and aberrant methylation of number of genes. The use of serum biomarkers that is non-invasive to discriminate cancer patients from healthy persons will prove to be an important tool to improve the early diagnosis of CRC. This will serve as the boon to the clinical management of the disease.
Indexed as
Identifiers
27844020PMC5019333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.